Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study (2022)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472201/

Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France (2022)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932274/?report=classic

Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort (2022)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768912/?report=classic

Characterization of Blood Mucosal‐Associated Invariant T Cells in Patients With Axial Spondyloarthritis and of Resident Mucosal‐Associated Invariant T Cells From the Axial Entheses of Non‐Axial Spondyloarthritis Control Patients (2022)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825958/?report=classic

Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials (2021)
https://doi.org/10.1016/j.berh.2014.10.008 - DOI - PubMed

Disease activity outcome measures are only available in half of the electronic medical files of patients with axial spondyloarthritis followed in an outpatient clinic: the results of an audit of a tertiary-care rheumatology department (2021)
https://doi.org/10.1007/s00296-021-05055-3

Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study (2021)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576480/